Are You Looking for a Top Momentum Pick? Why Exelixis (EXEL) is a Great ChoiceZacks Investment Research • 06/06/25
Exelixis (EXEL) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 05/23/25
Earnings Estimates Moving Higher for Exelixis (EXEL): Time to Buy?Zacks Investment Research • 05/23/25
EXEL Reports Superior Efficacy Data From Kidney Cancer Study CohortZacks Investment Research • 05/23/25
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025Business Wire • 05/22/25
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and JuneBusiness Wire • 05/22/25
Unlocking Exelixis (EXEL) International Revenues: Trends, Surprises, and ProspectsZacks Investment Research • 05/19/25
Exelixis Crushes Q1 Earnings Estimates With Strong Cabometyx Sales, Raises 2025 Revenue GuidanceBenzinga • 05/14/25
EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top LineZacks Investment Research • 05/14/25
Invenra Highlights Exelixis' Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid TumorsBusiness Wire • 05/13/25
Biotech Leader Exelixis Pops After Obliterating First-Quarter Profit ExpectationsInvestors Business Daily • 05/13/25